Navigation Links
Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
Date:2/13/2008

SOUTH SAN FRANCISCO, Calif., Feb. 13 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that it completed enrollment of patients in the maximum tolerated dose (MTD) cohort expansion segment of its Phase 1/2a trial of RAV12, an anti-cancer monoclonal antibody. The trial enrolled patients with cancers that express the RAAG12 antigen, particularly those of gastrointestinal origin. All patients in the trial have undergone radiographic re-evaluation to assess their response to treatment. Based on this assessment, two patients remain on study drug beyond the original treatment period. A total of four patients received extended therapy in both the original cohort and the expanded cohort of this trial.

"We continue to be pleased with our advances with RAV12 and the indications of its potential therapeutic value." said George Schreiner, M.D., Ph.D., chief executive officer of Raven biotechnologies.

RAAG12 is a glycotope (sugar structure) that is widely found on the surface of tumor cells of many kinds of cancer, particularly cancers of the gastrointestinal tract (adenocarcinomas of gastroesophageal, pancreatic and colorectal origin). RAV12, Raven's lead clinical monoclonal antibody drug candidate, targets the RAAG12 antigen.

An analysis of data from this trial is expected in the second or third quarter of this year. The analysis will produce an evaluation of safety, definitive pharmacokinetics, evaluation of immunogenicity, and estimates of efficacy in a refractory patient population.

The appropriate dose and schedule of RAV12 previously was chosen in a dose-escalation segment of the Phase 1/2a trial that involved 33 patients. This trial revealed that a fractionated dosing regimen provided an improved side effect profile for the antibody. The recently concluded MTD Cohort Expansion segment involved 20 additional patients. '/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: ... based on intellectual property developed and owned by ... foremost medical research center, today announced that its ... funding from the Israeli Ministry of Industry and ... support product development and advance clinical trials. Cell ...
(Date:5/23/2013)... , May 23, 2013  Every day, their baby stopped ... to his lungs. April and Bryan Gionfriddo ... weren,t true. "Quite a few doctors said he ... says April Gionfriddo , about her now ... that would work, we would take it and run with ...
(Date:5/23/2013)... May 23, 2013   Direct to implant, ... is an appropriate option for many women with ... reduce their breast cancer risk, or with breast ... process and a second surgery to insert permanent ... same surgery as mastectomy can be a medically ...
Breaking Medicine Technology:Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3
... ViroPharma Incorporated (Nasdaq: VPHM ) ... has granted ViroPharma an exclusive worldwide license to ... delivery platform using Halozyme,s recombinant human hyaluronidase enzyme ... inhibitor. Additionally, Halozyme has agreed not to grant to ...
... Henry Schein, Inc. (NASDAQ: HSIC ), the ... dental, medical and veterinary practitioners, has been ranked number 317 ... Largest Corporations.  Henry Schein,s net sales reached a record $7.5 ... 500 rankings over the past three years, having been ranked ...
Cached Medicine Technology:ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 2ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 3ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 4ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 5ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 6ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor 7Henry Schein Ranks #317 in 2011 Fortune 500 Ranking of America's Largest Corporations 2
(Date:5/25/2013)... York, NY (PRWEB) May 25, 2013 ... digestive problems, ranging from irritable bowel syndrome (IBS) ... problems are among the most long-lasting, embarrassing, frustrating ... natural foods for digestive health have ... While there are many factors contributing to digestive ...
(Date:5/25/2013)... According to a new market report,"Global Homeland ... MarketsandMarkets is expected to reach $544.02 Billion by ... and studies the major market drivers, restraints, and ... of the World. , Browse:, , ... 87 Figures , 175 Pages and ...
(Date:5/25/2013)... Vancouver, BC (PRWEB) May 25, 2013 ... of the most beautiful and powerful women that ever ... was felt by some of the most powerful men ... used many beauty remedies to keep her skin glowing ... treatments made with bees- wax, maringa oil and cyprus ...
(Date:5/25/2013)... IBISWorld estimates that revenue for the Cell ... of 28.7% to $1.0 billion in the five years to ... 2008, no new cell therapy products were introduced, according to ... that period. In the years since, however, the Food and ... contributed to the industry's fast growth during the five years ...
(Date:5/25/2013)... 25, 2013 Ayurveda is the ... wisdom of life". While a medical science, its scope enters ... consciousness. Its fundamental philosophy is that disease is the end ... order to re-establish optimal health, one must discover where we ... style which brings us back into perfect harmony. , The ...
Breaking Medicine News(10 mins):Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Fundamentos de Ayurveda in Mexico (Ayurvedic Principles) Offered by Escuela de Ayurveda de California 2
... April 28 AIDS Action Council commends President Obama and ... Goosby as Director of the Office of the Global AIDS ... of the Global AIDS Coordinator will be led by such ... experience in the breadth of global AIDS, including the epidemic ...
... 2009 (BRONX, NY) A laboratory study by researchers ... that an anti-cancer compound studied for treating blood cancers may ... The work is reported in the April 28th online edition ... neck cancer refers to tumors in the mouth, throat, or ...
... studies used to gain Food and Drug Administration approval of ... according to a report led by the University of Pittsburgh ... of the American Journal of Psychiatry , the study ... for these studies, and those who do not qualify are ...
... MCDONOUGH, Ga. , April 28 With growing ... the question has been raised, "Will face masks protect ... Encompass Group, the manufacturer of ProGear(TM), an innovative, technologically ... in the United States, stated, "At this time it ...
... Sciences, Inc. today announced that it named Dr. Robert ... a leader in pharmaceutical research to its Scientific Advisory ... & Development in 2008, and currently serves as a ... 2000 and has been responsible for all pharmaceutical research ...
... Starting to Embrace Use of Targeted Agents Despite ... Decision Resources WALTHAM, Mass., April 28 Decision ... advisory firms focusing on pharmaceutical and healthcare issues, ... Roche/Chugai,s Xeloda, Indian brand/generics (capecitabine) will dominate the ...
Cached Medicine News:Health News:AIDS Action Applauds Selection of Dr. Eric Goosby as Global AIDS Coordinator 2Health News:Experimental drug shows promise against head and neck cancer 2Health News:Are we cherry picking participants for studies of antidepressants? 2Health News:Will Face Masks Protect Against Swine Flu? 2Health News:Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB 2Health News:Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB 3Health News:Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013 2
Features four-way apron closure for super adjustability to fit staff of all shapes and sizes. Top left and right shoulder closures allow adjustment of armhole size and chest area of apron for close a...
Freedom of movement - plus full circle, maximum radiation protection. No other full circle radiation protection design approaches the level of comfort of the VestSkirt, which divides weight between t...
Use this workhorse apron where 360 of protection from direct and scatter radiation is required....
Bio-Rad's Genetic Systems™ HBsAg EIA 3.0 screening and confirmatory assays offer outstanding sensitivity and early detection of HBV infection, helping to meet your testing criteria....
Medicine Products: